Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, 6-Week, Double Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects With Bipolar Depression

NCT06696755 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06696755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06696755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, 6-Week, Double Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects With Bipolar Depression
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Recruiting
Start date
February 3, 2026
Completion date
November 30, 2027
Enrollment
195 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder, bipolar ii disorder